Successful Use of Cefepime-Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia.
Tirlangi Praveen KumarBala Saheb WanveRamakanth Reddy DubbuduBoorgula Sushma YadavL Siva KumarAnand GuptaRacha Amarthya SreeHari Priya Reddy ChallaP Naveen ReddyPublished in: Antimicrobial agents and chemotherapy (2023)
With limited and often toxic treatment options, carbapenem-resistant Gram-negative infections are associated with significant mortality. Cefepime-zidebactam is a promising antibiotic option undergoing a phase 3 trial that has activity against diverse antibiotic-resistant mechanisms in Gram-negative pathogens due to its β-lactam enhancer mechanism, mediating multiple PBP binding. We report a case of disseminated infection caused by a New Delhi metallo-β-lactamase-producing, extensively drug-resistant Pseudomonas aeruginosa isolate in a patient with acute T-cell leukemia, successfully managed with cefepime-zidebactam as a salvage therapy.
Keyphrases
- gram negative
- multidrug resistant
- drug resistant
- acinetobacter baumannii
- pseudomonas aeruginosa
- liver failure
- cystic fibrosis
- respiratory failure
- case report
- acute myeloid leukemia
- bone marrow
- drug induced
- biofilm formation
- aortic dissection
- cardiovascular events
- binding protein
- coronary artery disease
- type diabetes
- risk factors
- transcription factor
- escherichia coli
- replacement therapy
- dna binding
- cardiovascular disease